Can I Take Caffeine With Vyleesi (Bremelanotide)?

What Vyleesi Actually Is (and Who It Is For)

Vyleesi is a prescription injectable approved by the FDA in June 2019 specifically for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). HSDD is defined as persistently low sexual desire that causes personal distress, with no identifiable medical, psychiatric, or relationship explanation accounting for it fully.

The drug is not a hormone. It is a melanocortin receptor agonist, a synthetic peptide that activates MC1R, MC3R, and MC4R receptors in the central nervous system to modulate sexual desire pathways. You inject it subcutaneously in the abdomen, thigh, or upper arm at least 45 minutes before anticipated sexual activity. You use it no more than once in 24 hours, and no more than one dose per anticipated sexual event.

Who Has HSDD

Approximately 10 percent of U.S. Women meet criteria for HSDD at any given time, though prevalence rises in the perimenopausal transition and postpartum period. Vyleesi's FDA label restricts use to premenopausal women because both key trials, RECONNECT Study 301 and Study 302, enrolled only premenopausal participants. Postmenopausal use is not approved and carries no clinical-trial safety data.

Conditions That Overlap With HSDD

Women with PCOS, endometriosis, postpartum hormonal disruption, or those taking hormonal contraception that suppresses androgen levels may be more likely to report low desire. Research published in the Journal of Sexual Medicine found that women with untreated depression and women on SSRIs had significantly higher rates of HSDD than the general population. If any of these apply to you, discuss them with your prescriber before adding Vyleesi.

How Bremelanotide Works: The Pharmacology You Need to Know

Bremelanotide is a cyclic heptapeptide. After subcutaneous injection, it reaches peak plasma concentration in about 1 hour. Its half-life is approximately 2.7 hours, and it is metabolized primarily through peptide hydrolysis rather than cytochrome P450 enzymes.

This matters for the caffeine question.

CYP1A2: The Enzyme That Is Not the Main Issue

Caffeine is metabolized almost entirely by CYP1A2. Bremelanotide is not. The FDA label and pharmacokinetic studies do not identify CYP1A2 as a significant pathway for bremelanotide clearance, which means caffeine is unlikely to change bremelanotide blood levels in a meaningful way. The concern is not pharmacokinetic (one drug changing the other's concentration). The concern is pharmacodynamic: both substances independently raise blood pressure at the same time.

Bremelanotide's Known Cardiovascular Effect

The FDA prescribing information for Vyleesi documents that bremelanotide causes a transient increase in blood pressure peaking within approximately 12 minutes of injection and generally resolving within 12 hours. In clinical trials, the mean maximum increase was approximately 6 mmHg systolic and 3 mmHg diastolic. In some women, the increase exceeded 20 mmHg systolic. This is why Vyleesi carries a cardiovascular warning and why women with known hypertension or cardiovascular disease should not use it.

Caffeine and Blood Pressure: What the Data Show

Caffeine is the most widely consumed psychoactive substance in the world. A single 200 mg dose (roughly one to two standard cups of coffee) acutely raises systolic blood pressure by 3 to 15 mmHg in non-habituated individuals, with the peak occurring within 30 to 60 minutes. In habituated daily drinkers, the acute pressor effect is blunted but not eliminated. Energy drinks and pre-workout supplements can contain 150 to 300 mg of caffeine per serving, potentially delivering a larger pressor effect.

A 2012 meta-analysis in the Journal of Hypertension confirmed that caffeine raises both systolic and diastolic blood pressure acutely, with the effect lasting one to three hours. The magnitude depends on dose, tolerance, CYP1A2 genotype (slow metabolizers experience greater and longer pressor responses), and baseline blood pressure.

Caffeine Sources That Women Often Overlook

Caffeine is not only in coffee.

• Pre-workout powders: 150-300 mg per serving
• Matcha lattes: 50-80 mg per cup
• Energy drinks: 80-300 mg per can
• Headache medications (e.g., Excedrin): 65 mg per tablet
• Some fat-burning supplements: 200+ mg per dose
• Dark chocolate: 12-25 mg per ounce

If you take Vyleesi and use any of these near your injection time, you may be stacking pressor effects without realizing it.

The Combined Risk: Additive Blood Pressure Elevation

When you inject Vyleesi and consume caffeine within a similar time window, both are raising blood pressure through different mechanisms simultaneously. Bremelanotide's pressor effect is centrally mediated through melanocortin receptors. Caffeine's effect is primarily through adenosine receptor antagonism and catecholamine release. These pathways do not cancel each other; they add.

Here is a practical way to think about the combined window of risk. Bremelanotide is injected at least 45 minutes before sexual activity, peaks in blood pressure effect at around 12 minutes post-injection, and has an active pressor window of approximately one to two hours. Caffeine consumed in the 60 minutes before injection, or in the 90 to 120 minutes after, could overlap with bremelanotide's pressor peak. That overlap zone is where the risk concentrates.

A woman with baseline blood pressure of 120/80 mmHg could, in a plausible scenario, see a transient reading of 138-141/88-94 mmHg if both pressor effects peak together. For most healthy premenopausal women that is not dangerous. But for a woman whose blood pressure runs 130/85 at baseline, or who has white-coat hypertension, the combined spike could briefly push readings into stage 2 hypertension territory.

No clinical trial has directly studied the combined cardiovascular effect of bremelanotide plus caffeine. This is an evidence gap. The guidance below is extrapolated from each substance's individual pharmacodynamics, not from head-to-head trial data.

Timing Guidance: A Practical Caffeine Window

Based on the pharmacodynamic profiles of both substances:

| Time relative to Vyleesi injection | Caffeine recommendation | |---|---| | More than 3 hours before | Generally acceptable | | 1 to 3 hours before | Avoid or limit to <50 mg (half a small coffee) | | 0 to 90 minutes after injection | Avoid caffeine entirely | | 90 minutes to 3 hours after injection | Limit to <50 mg if used | | After 3 hours post-injection | Normal intake is reasonable |

This two-to-three-hour separation window on either side of your injection minimizes the overlap of peak pressor effects.

Blood Pressure Monitoring: What to Actually Do

The Vyleesi prescribing information instructs prescribers not to use bremelanotide in women with cardiovascular disease or uncontrolled hypertension. If you are otherwise healthy, formal blood pressure monitoring before each dose is not required in the label. But if you are combining Vyleesi with caffeine, or if your resting blood pressure tends to run above 130/80 mmHg, taking your blood pressure 15 to 20 minutes after your injection is a reasonable precaution.

Signs that warrant stopping use and calling your prescriber:

• Headache with visual changes
• Chest tightness or discomfort
• Palpitations lasting more than a few minutes
• Systolic reading above 160 mmHg on a home cuff

Sex-Specific Physiology: How Your Hormonal Status Affects This

Bremelanotide was studied exclusively in premenopausal women. Estrogen and progesterone fluctuate across the menstrual cycle, and this matters for blood pressure physiology.

Cycle Phase and Blood Pressure Variability

Blood pressure is not constant across the menstrual cycle. Research in the American Journal of Hypertension found that blood pressure tends to be slightly lower in the follicular phase and may rise mildly in the luteal phase in some women. If you already experience luteal-phase migraine or fluid retention, using Vyleesi with caffeine in your late luteal phase adds more cardiovascular load to an already slightly elevated baseline.

Hormonal Contraception

Many women using Vyleesi are also on hormonal contraception. Combined oral contraceptives themselves can raise blood pressure by 2 to 5 mmHg systolic in susceptible women. That adds a third potential pressor. If you are on the pill, use a progestin-only method, or have an IUD, discuss your cardiovascular baseline with your prescriber.

Perimenopause: Off-Label Territory

Vyleesi is not FDA-approved for postmenopausal or perimenopausal women. Perimenopausal women often experience vasomotor instability, and the estrogen decline of perimenopause is associated with rising blood pressure. Using bremelanotide off-label in this group, combined with caffeine, carries even less safety data than in premenopausal women. The Menopause Society (formerly NAMS) 2022 position statement on female sexual dysfunction notes that approved treatments for HSDD are limited to premenopausal populations, and clinicians should exercise caution with off-label extrapolation.

Pregnancy and Lactation: Required Reading If You Are Using Vyleesi

Vyleesi is contraindicated in pregnancy. This is not a precautionary soft contraindication. Animal studies showed fetal harm at doses above human therapeutic exposure, and the FDA label carries a clear warning to discontinue Vyleesi immediately if pregnancy is detected.

Pregnancy Category and Human Data

Bremelanotide has not been studied in pregnant humans. Based on animal reproductive toxicology data, the FDA assigns a risk level consistent with known fetal risk potential. No human pregnancy registry exists for bremelanotide at this time. Because Vyleesi is used on an as-needed basis rather than daily, a woman who discovers she is pregnant shortly after a dose should contact her obstetric provider, though a single inadvertent exposure before a recognized pregnancy is a different clinical scenario than ongoing use.

Contraception Requirement

Because bremelanotide is approved only for premenopausal women (who are by definition potentially fertile), reliable contraception is expected if pregnancy is not desired. ACOG guidance recommends long-acting reversible contraception (LARC) as the most effective options for women who want to avoid pregnancy while managing a condition like HSDD.

Lactation

There are no human lactation studies for bremelanotide. The FDA label states that the drug's presence in human breast milk is unknown. Given the half-life of approximately 2.7 hours, a breastfeeding woman who used Vyleesi could theoretically pump and discard milk for 12 to 16 hours after a dose as a precautionary measure. But this is extrapolation, not evidence-based guidance. The FDA recommends that breastfeeding women discuss the risks with their prescriber before using Vyleesi. Practically, HSDD in the postpartum period is common due to prolactin elevation and estrogen suppression, but Vyleesi has not been studied in this population specifically.

Who Vyleesi Is Right For (and Who Should Avoid It)

Likely Appropriate

• Premenopausal women with confirmed HSDD diagnosis causing personal distress
• Women with normal or well-controlled blood pressure at baseline
• Women not taking other pressor medications or stimulant supplements concurrently
• Women who can reliably avoid caffeine in the two-to-three-hour window around their injection

Use With Caution

• Women on combined oral contraceptives with borderline blood pressure
• Women who consume multiple caffeine sources daily and cannot reliably separate intake from dosing
• Women with migraine (Vyleesi can trigger nausea and headache independently)

Avoid Vyleesi

• Women who are pregnant or planning pregnancy imminently without reliable contraception
• Women with known cardiovascular disease, uncontrolled hypertension, or history of stroke
• Women who are breastfeeding unless they have had a detailed risk discussion with their provider
• Postmenopausal women outside of a clinical research setting

Other Supplements and Medications to Consider Alongside the Caffeine Question

The caffeine interaction is the most commonly asked about, but it is not the only supplement concern with Vyleesi.

Nausea-Exacerbating Supplements

Nausea affects approximately 40 percent of women who use bremelanotide in clinical trials, making it the most common reason for discontinuation. Supplements that independently trigger nausea or slow gastric motility may worsen this. Iron supplements, fish oil at high doses, and zinc on an empty stomach are common examples. Taking these near your Vyleesi dose is likely to compound gastrointestinal discomfort.

Other Stimulants

Guarana, synephrine, yohimbine, and high-dose green tea extract all have pressor effects. The same logic that applies to caffeine applies to these: pharmacodynamic stacking around your injection window is the concern.

Flibanserin (Addyi) and Vyleesi

These are two separate FDA-approved treatments for HSDD. They are not typically combined. Flibanserin carries its own interaction profile (it is a CYP3A4 substrate with a serious interaction with alcohol and moderate CYP3A4 inhibitors). If you are switching from flibanserin to Vyleesi, tell your prescriber.

The Evidence Gap: What We Do Not Know

Clinical trials for bremelanotide enrolled premenopausal women who met specific cardiovascular health criteria. They did not characterize interactions with caffeine, stimulant supplements, or herbal products. The RECONNECT trials (NCT02333071, NCT02338960) focused on efficacy endpoints (desire and distress scores) rather than supplement co-administration. Women from racial and ethnic minority groups were under-represented. Women with PCOS or endometriosis were not analyzed as distinct subgroups despite higher HSDD prevalence in those populations.

This means the guidance in this article is built on pharmacodynamic reasoning and each substance's individual trial data, not on a head-to-head study of the combination. That honesty matters. When a clinician or website tells you there is "no interaction," they are likely referring to the absence of a pharmacokinetic interaction at CYP enzymes. That is accurate. But it does not mean the combination is without any risk.

As WomanRx medical reviewer Dr. Elena Vasquez, OB-GYN, puts it: "The absence of a pharmacokinetic interaction does not mean absence of cardiovascular risk. Two pressor substances taken close together are additive by definition. My advice to patients is simple: treat the two-hour window around your Vyleesi injection like a caffeine fast, the same way you would hold stimulants before a cardiology appointment."

Practical Summary: Using Caffeine and Vyleesi Together Safely

1. Plan your Vyleesi dose around your caffeine habits, not the other way around.
2. Have your last caffeinated drink at least two to three hours before you plan to inject.
3. After injection, wait at least 90 minutes before resuming any caffeine.
4. If you use pre-workout supplements, energy drinks, or stimulant-containing fat burners, the same window applies and the doses in those products may be higher than in coffee.
5. If your resting blood pressure is consistently above 130/80 mmHg, raise this with your prescriber before starting Vyleesi regardless of caffeine use.
6. Keep a home blood pressure cuff available for the first few uses, particularly if you are not certain you can maintain caffeine separation.

Per the FDA Vyleesi prescribing information, the maximum frequency of use is one dose per 24-hour period, and no more than one dose per anticipated sexual event. Using it more frequently does not increase desire and does increase side-effect burden.